Male Infertility Market Size & Growth Forecast 2026–2035, By Segments (Treatment, Test), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Male Infertility Market size was over USD 4.53 Billion in 2025 and is likely to grow at a 5.1% CAGR between 2026 and 2035, reaching USD 7.45 Billion by 2035. The industry revenue for 2026 is assessed at USD 4.73 billion.

• Base Year Value (2025): USD 4.53 Billion
• CAGR (2026-2035): 5.1%
• Forecast Year Value (2035): USD 7.45 Billion
• Historical Data Period: 2022-2025
• Largest Region: Europe
• Forecast Period: 2026-2035

Male Infertility Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Europe accounted for 39.54% of the market in 2025, supported by established reproductive healthcare systems, specialist fertility clinics, structured referrals, and broad access to advanced diagnostics and treatments.
  • Asia Pacific is projected to grow at a 5.76% CAGR as fertility care access expands, specialist treatment infrastructure improves, and more patients enter diagnosis-led reproductive care pathways.

• Segment Momentum:

  • This segment held a 67.95% share in 2025 because it addresses a broad range of infertility causes and provides effective treatment pathways for clinically significant reproductive challenges.
  • Computer Assisted Semen Analysis is the fastest-growing segment as it improves testing consistency, reduces manual variability, and supports more standardized diagnostic workflows in fertility clinics.

• Market Expansion Drivers:

  • Rising global infertility rates driving increased adoption of assisted reproductive technologies.
  • Increasing use of DNA fragmentation testing improving male infertility diagnostics accuracy.
  • Lifestyle-related risk factors such as obesity and smoking increasing male reproductive health issues.

• Leading Market Participants:

  Major companies in the male infertility market include Bayer AG (Germany), Aytu BioPharma, Inc. (United States), Cadila Pharmaceuticals Limited (India), Halotech DNA, S.L. (Spain), Merck KGaA (Germany), Intas Pharmaceuticals Ltd. (India), CooperSurgical, Inc. (United States), Vitrolife AB (Sweden), Ferring Pharmaceuticals (Switzerland), SCSA Diagnostics, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 4.53 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 7.45 Billion by 2035
  • Growth Forecasts: 5.1% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: Europe
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Assisted Reproductive Technology and Varicocele Surgery (Treatment) | DNA Fragmentation Technique (Test)
  • Emerging Opportunity Segment: Assisted Reproductive Technology and Varicocele Surgery (Treatment) | Computer Assisted Semen Analysis (Test)

Market Growth Drivers and Industry Trends

Rising global infertility rates driving increased adoption of assisted reproductive technologies

As infertility becomes more common among couples, clinical pathways are shifting toward earlier and more frequent use of assisted reproductive technologies, which is directly strengthening demand in the male infertility market. Male-factor evaluation is increasingly embedded in fertility workups before or alongside ART procedures such as IVF and ICSI, prompting higher utilization of semen analysis, hormonal assessment, sperm retrieval procedures, and adjunct male fertility treatments. In practice, rising ART adoption also changes provider behavior: fertility centers expand andrology capabilities, physicians recommend faster diagnostic escalation for men with suboptimal reproductive parameters, and patients who might previously have delayed care are drawn into structured treatment pathways that increase market penetration for male infertility services and related therapeutics.

Increasing use of DNA fragmentation testing improving male infertility diagnostics accuracy

Greater use of DNA fragmentation testing is reshaping clinical decision-making in the male infertility market by identifying sperm quality issues that conventional semen analysis often misses. This improves diagnostic precision for men with unexplained infertility, recurrent pregnancy loss, or failed ART cycles, allowing clinicians to refine treatment selection rather than relying on broad empirical approaches. As a result, fertility specialists are more willing to incorporate advanced male testing into standard evaluations, encouraging market growth for specialized diagnostics while also increasing downstream demand for targeted interventions, including antioxidant therapy, varicocele management, sperm selection strategies, and testicular sperm retrieval in carefully selected cases.

Lifestyle-related risk factors such as obesity and smoking increasing male reproductive health issues

The growing burden of obesity, smoking, stress, poor diet, and related lifestyle risks is contributing to a larger pool of men presenting with impaired sperm quality, hormonal imbalance, and subfertility, reinforcing market demand in the male infertility market. These factors often produce chronic, multifactorial reproductive problems that require repeated assessment and longer treatment journeys rather than a single diagnostic visit, which supports sustained utilization of laboratory testing, specialist consultations, hormone-based management, and fertility planning services. In practice, this trend is also pushing clinicians to integrate reproductive evaluation with broader metabolic and behavioral risk assessment, making male infertility care more proactive and increasing adoption of structured treatment pathways.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of male infertility	1.80%	Short term (≤ 2 yrs)	North America, Europe (spillover: Asia Pacific)	High	Fast
Adoption of advanced diagnostics and treatments	1.70%	Medium term (2–5 yrs)	Europe, Asia Pacific (spillover: North America)	Medium	Moderate
Expansion of fertility clinics and telemedicine solutions	1.60%	Long term (5+ yrs)	North America, Europe (spillover: Asia Pacific)	Medium	Slow
Rising global infertility rates driving increased adoption of assisted reproductive technologies	2.90%	High	Europe, Asia Pacific	High	Near Term
Increasing use of DNA fragmentation testing improving male infertility diagnostics accuracy	2.40%	Moderate	North America, Europe	Medium	Mid Term
Lifestyle-related risk factors such as obesity and smoking increasing male reproductive health issues	2.60%	Moderate	North America, Asia Pacific	High	Near Term

Regional Demand Dynamics

Europe (Largest Region) vs Asia Pacific (Fastest-Growing Region)

Europe held a 39.54% share of the male infertility market in 2025, bolstered by well-established reproductive healthcare systems, broad availability of specialist fertility clinics, and greater integration of diagnostic testing into routine clinical pathways. The region’s leadership is reinforced by higher treatment awareness and more structured patient referral patterns, which help move men from initial evaluation to specialist consultation and treatment more efficiently. In practice, this supports steady procedure volumes, wider use of laboratory-based assessments, and more consistent adoption of advanced therapeutic options across major healthcare markets.

Asia Pacific is projected to expand at a 5.76% CAGR over the forecast period, with growth in the male infertility market being propelled by rising access to fertility care and a gradual broadening of treatment infrastructure across urban healthcare centers. Adoption is accelerating as more patients enter the formal care pathway through improving diagnostic availability and expanding specialist services, particularly where private fertility providers are increasing capacity. This creates a more active treatment environment, with demand building not only from awareness of reproductive health issues but also from the growing ability of providers to convert consultations into diagnosis-led intervention.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Supportive	Neutral	Supportive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Comprehensive Fertility Care

The U.S. male infertility market benefits from broader access to reproductive diagnostics, fertility clinics, and assisted reproductive technologies. Healthcare providers increasingly promote earlier evaluation and personalized treatment pathways for male reproductive health.

Japan

Early Assessment Focus

Japan is encouraging earlier assessment of male infertility as awareness of reproductive health continues to improve. Fertility clinics increasingly integrate advanced diagnostics with personalized treatment plans to address diverse underlying causes.

South Korea

Specialized Fertility Services

South Korea continues expanding specialized fertility services that include comprehensive male infertility evaluation and treatment. Healthcare providers increasingly combine advanced diagnostics with assisted reproductive technologies to support individualized patient care.

Germany

Diagnostic Pathway Enhancement

Germany prioritizes evidence-based diagnosis and multidisciplinary management within the male infertility market. Fertility specialists increasingly adopt advanced laboratory testing and individualized treatment strategies to improve clinical decision-making.

France

Integrated Reproductive Care

France supports the male infertility market through coordinated reproductive healthcare and wider access to fertility assessments. Clinical practice increasingly emphasizes identifying male factors early to improve overall treatment planning for couples.

Italy

Personalized Treatment Approach

Italy is strengthening male infertility services through improved diagnostic capabilities and specialized fertility centers. Healthcare professionals increasingly tailor treatment plans according to individual clinical profiles and reproductive goals.

Segment Leadership and Growth Trends

  Treatment Segment Analysis: Assisted Reproductive Technology and Varicocele Surgery (Largest & Fastest-Growing Segment)

Assisted Reproductive Technology and Varicocele Surgery held a 67.95% share of the male infertility market in 2025, reflecting its established role in addressing clinically significant infertility cases where direct intervention is often required. its position is underpinned by the practical treatment value these approaches offer across a wide range of male infertility causes, from structural issues corrected through varicocele surgery to complex conception challenges managed through assisted reproductive procedures. The same clinical relevance is also supporting continued growth in the male infertility market, as patients and providers increasingly favor treatment pathways that can move beyond diagnosis and deliver clearer reproductive outcomes when conventional options are limited.

Test Segment Analysis: DNA Fragmentation Technique (Largest Segment) vs Computer Assisted Semen Analysis (Fastest-Growing Segment)

Within the male infertility market, DNA Fragmentation Technique accounted for a 23.51% share in 2025, making it the leading test segment. Its position is aided by the growing need for deeper sperm quality assessment beyond routine semen parameters, especially in cases where standard findings do not fully explain infertility outcomes. This keeps DNA Fragmentation Technique central to male infertility evaluation, as it helps clinicians investigate underlying reproductive issues with greater specificity in relevant patient groups.

Computer Assisted Semen Analysis is emerging as the fastest-growing test segment in the male infertility market because it improves the consistency and efficiency of semen assessment in clinical settings. Its momentum is tied to the practical advantage of reducing manual variability while enabling more standardized analysis, which is increasingly important as testing volumes rise and providers seek more reproducible diagnostic workflows. Compared with conventional assessment approaches, this stronger operational fit is helping Computer Assisted Semen Analysis gain traction more quickly.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Treatment	Assisted Reproductive Technology and Varicocele Surgery, Medication	Assisted Reproductive Technology and Varicocele Surgery	Assisted Reproductive Technology and Varicocele Surgery
Test	DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer Assisted Semen Analysis, Sperm Penetration Assay, Others	DNA Fragmentation Technique	Computer Assisted Semen Analysis

Competitive Landscape and Market Positioning

Top players in the male infertility market:

1. Bayer AG (Germany)

2. Aytu BioPharma Inc. (United States)

3. Cadila Pharmaceuticals Limited (India)

4. Halotech DNA S.L. (Spain)

5. Merck KGaA (Germany)

6. Intas Pharmaceuticals Ltd. (India)

7. CooperSurgical Inc. (United States)

8. Vitrolife AB (Sweden)

9. Ferring Pharmaceuticals (Switzerland)

10. SCSA Diagnostics Inc. (United States)

The male infertility market is witnessing increased attention due to rising awareness and diagnostic advancements. Improved therapeutic approaches are enabling more targeted treatment pathways. The male infertility market is also shaped by innovation in reproductive technologies and personalized care models. Continuous development is expanding access to effective fertility solutions.

Industry Development/News

Company Name	Date	Key Development
Ontario Government	May-26	The provincial government’s $100 million investment to expand publicly funded fertility services significantly bolsters reproductive healthcare infrastructure. This initiative improves patient access to diagnostic pathways and treatments, indirectly supporting a broader patient base and increasing clinical demand for male-factor infertility services across the healthcare system.
Nova IVF Fertility	Jul-25	The opening of the company's 100th fertility center marks a major expansion of its clinical footprint across 63 Indian cities. By increasing accessibility in tier 2 and tier 3 regions, this expansion enhances the distribution network for assisted reproductive services and addresses growing demand for specialized fertility diagnostics and treatment.
Farwaniya Hospital	Aug-24	The inauguration of a new Fertility and Assisted Reproduction Unit in Kuwait significantly enhances national reproductive healthcare capacity. By providing comprehensive diagnostic testing and advanced treatment options, the facility strengthens the local healthcare infrastructure and improves access to specialized reproductive technologies for patients within the region.
Archish Fertility & IVF	Jul-24	The launch of a new facility in HSR Layout, India, expands the provider’s clinical network and regional reach. The unit integrates specialized male infertility diagnostics and treatment into its service offerings, strengthening local market access to comprehensive reproductive healthcare and supporting the firm's overall competitive positioning in fertility services.
Ferring Pharmaceuticals	Jun-24	The launch of a digital assessment tool and educational platform represents a strategic move to optimize the patient funnel toward early diagnosis. By addressing awareness gaps, the platform facilitates better patient engagement and clinical navigation, ultimately supporting the commercialization of diagnostic and treatment pathways within the male infertility segment.
FertGroup; Future Fertility	Apr-24	The strategic partnership to deploy AI-enabled oocyte assessment software across Brazilian clinics represents a material advancement in digital reproductive analytics. This technology integration improves clinical decision-making and standardizes embryo evaluation processes, enhancing the quality of care and operational efficiency within the provider’s network to drive better treatment outcomes.
AINU Chennai	Feb-24	The inauguration of a dedicated andrology department provides a consolidated hub for male-specific reproductive healthcare. By integrating specialized diagnostics, sexual dysfunction management, and advanced infertility treatments, the institution strengthens its clinical infrastructure and enhances its capacity to manage complex male-factor infertility cases with a specialized, multidisciplinary approach.